Medication info
Dapaen 10 mg (Dapagliflozin Propanediol Hydrate)

Dapaen 10 mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets - 30 tablets/bottle
Approval status
Active

MFDS item code 202300388 · Approved 2023.01.30 · Insurance code 640007870

Summary

Main use
Treatment of type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy: The recommended dose of this drug is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy: For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this drug when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease: The recommended dose of this drug is 10 mg once daily. Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - eGFR less than 25 mL/min/1.73m2: Initiation of this drug is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this drug. Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years): Dose adjustment based on age is not recommended. Method of administration: This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. There are no relevant data.

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease

  • Type 2 diabetes
  • glycemic control disorders
  • chronic heart failure
  • cardiovascular disease
  • chronic kidney disease
  • estimated glomerular filtration rate reduction
  • end-stage kidney disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. It also helps reduce the risk of death and hospitalization related to cardiovascular disease in patients with chronic heart failure. In patients with chronic kidney disease, it plays a role in delaying the progression of kidney function deterioration and reducing the risk of cardiovascular disease and kidney-related mortality. Thus, this medication contributes to the management of significant chronic conditions such as diabetes, heart failure, and kidney disease, improving patients' health status.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy: The recommended dose of this drug is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy: For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this drug when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease: The recommended dose of this drug is 10 mg once daily. Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - eGFR less than 25 mL/min/1.73m2: Initiation of this drug is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this drug. Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years): Dose adjustment based on age is not recommended. Method of administration: This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. There are no relevant data.

Precautions

This medication should not be used in patients with allergies to its active ingredient or excipients or in those with type 1 diabetes or diabetic ketoacidosis. Additionally, patients with genetic lactase deficiency or those undergoing dialysis should not take this medication. This medication should be used cautiously in patients with reduced fluid volume or impaired kidney function. It can lower blood pressure or affect kidney function, especially requiring more attention in elderly patients or those taking specific diuretics. Fluid status and kidney function should be assessed before starting treatment, and symptoms of hypotension and kidney function should be regularly monitored during treatment. Side effects may include genital infections, urinary tract infections, hypoglycemia, reduction in fluid volume, and ketoacidosis. Genital infections are particularly common in females and those with a history of previous infections. In severe cases, a serious infection called perineal gangrene (Fournier's gangrene) may occur, so if pain, swelling, or redness occurs around the genital area, immediate consultation with a healthcare provider is necessary. The risk of hypoglycemia may increase when this medication is used in conjunction with insulin or sulfonylureas, so dosage adjustments of these drugs may be necessary. Pregnant or lactating women should not take this medication, and treatment should be discontinued upon confirmation of pregnancy. The safety and efficacy of this medication in pediatric patients have not yet been established, so its use is not recommended. There is no specific antidote for overdose, so appropriate treatment should be provided based on symptoms, and healthcare providers should be notified immediately if needed. Care should be taken during driving or operating machinery while taking this medication, particularly if there is a risk of hypoglycemia. Finally, this medication should be kept out of reach of children and stored in its original container to maintain quality.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, lumbago, dysuria, polyuria, nocturia, interstitial nephritis, vulvar pruritus, genital pruritus, elevated hematocrit, decreased renal creatinine clearance at the beginning of treatment, dyslipidemia, elevated serum creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, chest pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, angioedema, weakness, pain, ligament sprain, traffic accident, drug overdose, ankle fracture, hand fracture, pelvic fracture, meniscus injury, thoracic spine fracture, tibia fracture, erythrocytosis, dyspepsia, nausea, diarrhea, vomiting, urinary retention, increased serum lactate, lymphocytopenia, vitamin D deficiency, decreased appetite, next symptom, headache, sensory impairment, nasopharyngitis, upper respiratory infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, influenza-like symptoms, vaginal discharge, irregular menstruation, pruritus, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.